🔗 Share this article

As the US continues making unprecedented changes to its vaccine recommendations, one figure has emerged unexpectedly: Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has concentrated on alleged deaths after Covid vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities planned to unveil major revisions to the pediatric immunization program earlier this month, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for benefit. This reveal has been delayed until the coming year.

Instead of the top vaccines chief, Høeg is set to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the office this year.

Consolidating Power at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood immunization guidelines in the US in order to be more in line with Denmark's approach, a country with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been standard for previous leaders of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in leading a major agency. She has no expertise in drug approvals.”

Former heads of the center would “understand laws and regulations and the research of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she lacks the type of experience that former directors who led the center have had.”

This division has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and every single one must be supervised,” she explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the position, which manages more than 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Disputed Programs

When asked about questions about Dr. Høeg's credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a representative said that the “concerns stem from inaccurate assumptions”.

“Her resume aligns with the responsibilities of her role,” the representative said, citing the months Dr. Høeg spent guiding the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a controversial rapid therapy clearance system that allegedly worried her preceding directors. “How are these drugs being selected for this fast-track system? Who is making the decisions?” Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he said, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, aside from shots.”

Public History on Immunizations

With immunizations, Høeg has a clearer, if troubling, history, Howard said. She authored a study using non-validated volunteer-provided data to assess the rate of heart inflammation after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are riskier than they are.

Among her “desired changes” for the current government featured revising guidelines for recently developed shots and ending “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an complete dogmatist who commences with her preconceived notions and reverse-engineers to fit the science in a extremely deceptive, dishonest fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|